Top Markets
#1 Zora Zora +32.72%
#2 SAFEcoin SAFEcoin +24.00%
#3 0G 0G +21.53%
#4 Full Moon Full Moon +18.68%
#5 Merlin's Seal BTC Merlin's Seal BTC +16.67%
#6 Axelar Axelar +16.33%
#7 VVS Finance VVS Finance +15.88%
#8 SkyAI SkyAI +14.30%
#9 Cysic Cysic +14.24%
#10 Apertum Apertum +14.01%
Coin of the day
Zora Zora
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Albireo Pharma, Inc. Albireo Pharma, Inc.

Albireo Pharma, Inc.

ALBO
Rangering i aksjer #12828
Albireo Pharma, Inc. is a biopharmaceutical company with marketed products,... Albireo Pharma, Inc. is a biopharmaceutical company with marketed products, dedicated to researching, developing, and commercializing new treatments that modify bile acids. The company primarily targets rare liver diseases in children, as well as various other conditions affecting the liver or digestive system. Its portfolio includes Bylvay, a treatment approved for progressive familial intrahepatic cholestasis. Bylvay is also in advanced (Phase III) clinical trials for further pediatric indications such as biliary atresia and Alagille syndrome, which are both uncommon and serious childhood disorders. Additionally, Albireo offers Elobixibat, prescribed for the management of persistent constipation and other functional gastrointestinal issues. Albireo is further advancing its pipeline with A3907, currently undergoing early-stage (Phase I) clinical investigation for adult liver diseases, and A2342, a preclinical candidate designed to address adult viral and liver conditions. The company holds a licensing agreement with EA Pharma Co., Ltd. concerning the development and market rollout of Elobixibat. Albireo Pharma, Inc.'s headquarters are located in Boston, Massachusetts.
Aksjekurs
$44.15
Sist synkronisert: 2023-03-02
Markedsverdi
$545.52M
Endring (1 dag)
-0.23%
Endring (1 år)
0.00%
Land
US
Handel Albireo Pharma, Inc. (ALBO)

Kategori

Healthcare
P/E-forhold for Albireo Pharma, Inc. (ALBO)
P/E-forhold per 2026 TTM: 0
Ifølge Albireo Pharma, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Albireo Pharma, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.